Seattle Genetics, Inc.

Seattle Genetics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Seattle Genetics, Inc. is not a good growth stock. Seattle Genetics, Inc. is not very popular among insiders. Seattle Genetics, Inc. is a mediocre stock to choose.

Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercializ...

News

Pharma Continues Its Ongoing Battle Against Cancer

Benzinga Last Tuesday, Pfizer Inc (NYSE: PFE) said it expects to close its $43 billion deal to buy cancer drugmaker Seagen Inc (NASDAQ: SGEN) later this week.\n more…

Yarbrough Capital LLC Sells 2,417 Shares of Seagen Inc. (NASDAQ:SGEN)

Ticker Report Yarbrough Capital LLC lowered its position in Seagen Inc. (NASDAQ:SGEN Free Report) by 53.4% during the 3rd quarter, Holdings Channel reports. The firm owned 2,109 shares of the biotechnology...\n more…

Syquant Capital Sas Takes Position in Seagen Inc. (NASDAQ:SGEN)

Ticker Report Syquant Capital Sas acquired a new stake in Seagen Inc. (NASDAQ:SGEN Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities Exchange...\n more…

California State Teachers Retirement System Cuts Position in Seagen Inc. (NASDAQ:SGEN)

Zolmax California State Teachers Retirement System trimmed its position in Seagen Inc. (NASDAQ:SGEN Free Report) by 0.3% during the second quarter, according to the company in its most recent 13F...\n more…

Daymark Wealth Partners LLC Sells 718 Shares of Seagen Inc. (NASDAQ:SGEN)

Ticker Report Daymark Wealth Partners LLC trimmed its holdings in Seagen Inc. (NASDAQ:SGEN Free Report) by 1.1% in the third quarter, according to the company in its most recent filing with the SEC. The...\n more…

Pfizer finds room for ADC snack after swallowing Seagen, inking deal for mesothelin candidate

FierceBiotech.com - Biotech Pfizer finds room for ADC snack after swallowing Seagen, inking deal for mesothelin candidate\nntaylor\nFri, 12/15/2023 - 06:39...\n more…